The Long Road
Emma Richardson, a 37-year-old marketing director from Brisbane, spent nearly six years trying to conceive before finally holding her daughter. Testing at age 32 revealed diminished ovarian reserve: AMH just 0.7 ng/mL, day-three FSH 13.1 IU/L, and an antral follicle count of only 6–7. Her diagnosis was unexplained DOR, and the prognosis from her Brisbane specialist was guarded.
Over four years, Emma endured three full IVF cycles at two leading Brisbane clinics. Her first antagonist protocol (300 IU Gonal-F) yielded four eggs, one 3BC blastocyst that failed implantation. A long down-regulation cycle at maximum stimulation produced just three eggs; all fertilized but arrested at day three. A microflare protocol showed improvement: five eggs, two early blastocysts transferred — and a chemical pregnancy that gave them three days of hope. After AU$45,000, her specialist recommended donor eggs.
A Different Approach
Unwilling to abandon genetic motherhood, Emma researched international options. She discovered China had become a global leader in treating DOR, with success rates exceeding Australian benchmarks. Complete IVF-ICSI-PGT-A cycles cost AU$10,000–$13,000 — roughly one-quarter of Australian prices. Through forums, she connected with Australian women treated in Guangzhou; SSAnkang was repeatedly recommended for transparent pricing, English-speaking coordinators, and hospital partnerships.
Pre-Treatment Planning
SSAnkang arranged a comprehensive remote consultation. Emma submitted all three Australian cycle records, five years of blood work, and her husband's semen analysis with DNA fragmentation results. A senior Guangzhou specialist proposed a modified ultra-long protocol with three months of pretreatment: DHEA 75 mg, CoQ10 ubiquinol 600 mg, melatonin 3 mg nightly, and — critically — recombinant growth hormone (somatropin 4 IU daily) for two months pre-stimulation, targeting follicular recruitment and oocyte quality. After disciplined adherence and weekly telemedicine, Emma and Michael flew to Guangzhou in September 2024.
The Guangzhou Cycle
Stimulation used combined recombinant FSH (Gonal-F 375 IU) and highly purified HMG (Menopur 150 IU) with continued low-dose GH, plus a GnRH antagonist (Cetrotide) from day six. By day eight, ultrasound showed nine follicles at 12–16 mm — already surpassing any Australian cycle. Dual trigger (hCG 10,000 IU + triptorelin 0.2 mg) was given on day twelve, with twelve follicles at 18–22 mm and peak estradiol of 8,240 pmol/L — a response her Brisbane doctor had never seen. Retrieval yielded twelve eggs; nine mature. ICSI resulted in seven fertilized oocytes. Time-lapse culture produced three expanded blastocysts. PGT-A confirmed two euploid embryos: a 4AA male and a 4AB female — Emma's first genetically normal embryos after six years.
The Transfer
Emma returned eight weeks later for a programmed frozen transfer. Endometrial preparation with oral estradiol valerate (Progynova 6 mg) achieved a 9.2 mm trilaminar lining. Luteal support combined intramuscular progesterone-in-oil (50 mg) with vaginal gel (Crinone 8%). The 4AB female blastocyst thawed with 100% survival. Beta HCG at 10 days post-transfer was 287 mIU/mL; at 12 days it reached 742 mIU/mL (35-hour doubling time). The six-week scan confirmed a single intrauterine pregnancy with a fetal heart rate of 128 bpm.
A New Chapter
Emma delivered Charlotte Mei Richardson in June 2025 at 39 weeks — a healthy 3.4 kg baby girl. She reflects: "We spent nearly fifty thousand dollars and endured years of heartbreak in Australia. In Guangzhou, with SSAnkang's meticulous guidance and a protocol genuinely tailored to my body, we finally became parents. The total cost — flights, accommodation, medications, the full ICSI-PGT-A cycle, and frozen transfer — was approximately AU$11,500, less than a single failed cycle at home. My only regret is not deciding sooner." Emma and Michael plan to return for their remaining euploid male embryo.